NASDAQ:CMRX Chimerix (CMRX) Stock Price, News & Analysis $0.88 0.00 (0.00%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$0.85▼$0.8950-Day Range$0.77▼$1.0752-Week Range$0.75▼$1.30Volume111,220 shsAverage Volume400,630 shsMarket Capitalization$78.52 millionP/E RatioN/ADividend YieldN/APrice Target$8.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Chimerix alerts: Email Address Chimerix MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside870.3% Upside$8.50 Price TargetShort InterestHealthy2.11% of Float Sold ShortDividend StrengthN/ASustainability-2.49Upright™ Environmental ScoreNews Sentiment0.96Based on 3 Articles This WeekInsider TradingSelling Shares$1,067 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.86) to ($1.04) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.62 out of 5 starsMedical Sector70th out of 910 stocksPharmaceutical Preparations Industry27th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingChimerix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageChimerix has only been the subject of 2 research reports in the past 90 days.Read more about Chimerix's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.11% of the float of Chimerix has been sold short.Short Interest Ratio / Days to CoverChimerix has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Chimerix has recently decreased by 10.58%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldChimerix does not currently pay a dividend.Dividend GrowthChimerix does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreChimerix has received a 58.63% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Pox medications" and "Clinical research services for cancer" products. See details.Environmental SustainabilityThe Environmental Impact score for Chimerix is -2.49. Previous Next 3.3 News and Social Media Coverage News SentimentChimerix has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Chimerix this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for CMRX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added Chimerix to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Chimerix insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,067.00 in company stock.Percentage Held by Insiders13.10% of the stock of Chimerix is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions45.42% of the stock of Chimerix is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Chimerix's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Chimerix are expected to decrease in the coming year, from ($0.86) to ($1.04) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Chimerix is -0.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Chimerix is -0.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioChimerix has a P/B Ratio of 0.50. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Chimerix's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Timothy SykesTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…Click here to see a unique election-year trade About Chimerix Stock (NASDAQ:CMRX)Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.Read More CMRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CMRX Stock News HeadlinesSeptember 3, 2024 | markets.businessinsider.comChimerix to Present at H.C. Wainwright 26th Annual Global Investment ConferenceAugust 30, 2024 | globenewswire.comChimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)September 7, 2024 | Porter & Company (Ad)Why billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. August 28, 2024 | americanbankingnews.comChimerix (NASDAQ:CMRX) Upgraded to "Hold" at StockNews.comAugust 22, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Chimerix (CMRX) and Ocuphire Pharma (OCUP)August 21, 2024 | uk.finance.yahoo.comChimerix Inc (CXF.DU)August 14, 2024 | finance.yahoo.comQ2 2024 Chimerix Inc Earnings CallAugust 14, 2024 | nz.finance.yahoo.comChimerix, Inc. (CXF.F)September 7, 2024 | Porter & Company (Ad)Why billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. August 14, 2024 | msn.comWHO declares mpox in Africa is a global health emergencyAugust 14, 2024 | msn.comChimerix, Inc. (NASDAQ:CMRX) Q2 2024 Earnings Call TranscriptAugust 13, 2024 | msn.comSwiss Funding Bodies ‘Talk Money’ and Co-Financing Opportunities at Locarno: ‘We Create a Space Where Stories Take Shape’August 13, 2024 | markets.businessinsider.comChimerix earnings preview: what Wall Street is expectingAugust 13, 2024 | finance.yahoo.comChimerix Reports Second Quarter 2024 Financial Results and Provides Operational UpdateAugust 13, 2024 | seekingalpha.comChimerix, Inc. (CMRX) Q2 2024 Earnings Call TranscriptAugust 12, 2024 | msn.comChimerix Q2 2024 Earnings PreviewJuly 5, 2024 | globenewswire.comChimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 30, 2024 | globenewswire.comChimerix to Participate in Fireside Chat at Jefferies Global Healthcare ConferenceSee More Headlines Receive CMRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Chimerix and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/13/2024Today9/07/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CMRX CUSIPN/A CIK1117480 Webwww.chimerix.com Phone(919) 806-1074Fax919-806-1146Employees90Year Founded2000Price Target and Rating Average Stock Price Target$8.50 High Stock Price Target$11.00 Low Stock Price Target$6.00 Potential Upside/Downside+870.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-82,100,000.00 Net Margins-25,337.96% Pretax Margin-58,820.14% Return on Equity-46.35% Return on Assets-41.80% Debt Debt-to-Equity RatioN/A Current Ratio6.94 Quick Ratio6.94 Sales & Book Value Annual Sales$144,000.00 Price / Sales545.25 Cash FlowN/A Price / Cash FlowN/A Book Value$1.74 per share Price / Book0.50Miscellaneous Outstanding Shares89,630,000Free Float77,888,000Market Cap$78.52 million OptionableOptionable Beta1.20 Social Links 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Michael T. Andriole M.B.A. (Age 51)CEO, President & Director Comp: $820kDr. Roy W. Ware MBAPh.D., Chief Manufacturing Technology OfficerKey CompetitorsFortress BiotechNASDAQ:FBIOChiasmaNASDAQ:CHMANature's Sunshine ProductsNASDAQ:NATRAtea PharmaceuticalsNASDAQ:AVIRAC ImmuneNASDAQ:ACIUView All CompetitorsInsiders & InstitutionsArmistice Capital LLCSold 40,000 shares on 8/15/2024Ownership: 2.481%Marshall Wace LLPBought 156,076 shares on 8/14/2024Ownership: 0.174%Renaissance Technologies LLCSold 370,637 shares on 8/9/2024Ownership: 1.655%Michael T AndrioleSold 1,285 sharesTotal: $1,066.55 ($0.83/share)Assenagon Asset Management S.A.Sold 49,759 shares on 7/18/2024Ownership: 0.452%View All Insider TransactionsView All Institutional Transactions CMRX Stock Analysis - Frequently Asked Questions How have CMRX shares performed this year? Chimerix's stock was trading at $0.9625 at the start of the year. Since then, CMRX shares have decreased by 9.0% and is now trading at $0.8760. View the best growth stocks for 2024 here. How were Chimerix's earnings last quarter? Chimerix, Inc. (NASDAQ:CMRX) announced its quarterly earnings results on Tuesday, August, 13th. The biopharmaceutical company reported ($0.23) EPS for the quarter, meeting the consensus estimate of ($0.23). The biopharmaceutical company earned $0.13 million during the quarter, compared to analysts' expectations of $1.26 million. Chimerix had a negative net margin of 25,337.96% and a negative trailing twelve-month return on equity of 46.35%. Who are Chimerix's major shareholders? Chimerix's top institutional investors include Armistice Capital LLC (2.48%), Renaissance Technologies LLC (1.65%), Assenagon Asset Management S.A. (0.45%) and Marshall Wace LLP (0.17%). Insiders that own company stock include Michael T Andriole, David Jakeman, Michelle Laspaluto, Fred A Middleton and Robert J Meyer. View institutional ownership trends. How do I buy shares of Chimerix? Shares of CMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Chimerix own? Based on aggregate information from My MarketBeat watchlists, some other companies that Chimerix investors own include Melinta Therapeutics (MLNT), Immunomedics (IMMU), Synergy Pharmaceuticals (SGYP), Novavax (NVAX), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX) and Inovio Pharmaceuticals (INO). This page (NASDAQ:CMRX) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chimerix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Chimerix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.